Page 25 - Read Online
P. 25

Zhang et al. Hepatoma Res 2020;6:30  I  http://dx.doi.org/10.20517/2394-5079.2020.17                                            Page 13 of 16


               12.  Schelhorn J, Best J, Dechêne A, Göbel T, Bertram S, et al. Evaluation of combined Gd-EOB-DTPA and gadobutrol magnetic resonance
                   imaging for the prediction of hepatocellular carcinoma grading. Acta Radiologica 2016;57:932-8.
               13.  Navin PJ, Venkatesh SK. Hepatocellular carcinoma: state of the art imaging and recent advances. J Clin Transl Hepatol 2019;7:72-85.
               14.  Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J
                   Hepatol 2013;58:169-77.
               15.  Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis,
                   response assessment, and treatment. Curr Prob Diagn Radiol 2015;44:479-86.
               16.  Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, et al. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J
                   Surg Oncol 2007;95:311-6.
               17.  Himeno H, Enzan H, Saibara T, Onishi S, Yamamoto Y. Hitherto unrecognized arterioles within hepatocellular carcinoma. J Pathol
                   1994;174:217-22.
               18.  Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, et al. Progression to hypervascular hepatocellular carcinoma: correlation with
                   intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143-9.
               19.  Ye XD, Yuan Z, Zhang J, Yuan Z. Radiological biomarkers for assessing response to locoregional therapies in hepatocellular carcinoma:
                   From morphological to functional imaging (Review). Oncol Rep 2017;37:1337-46.
               20.  Feng Y, Qin XC, Luo Y, Li YZ, Zhou X. Efficacy of contrast-enhanced ultrasound washout rate in predicting hepatocellular carcinoma
                   differentiation. Ultrasound Med Biol 2015;41:1553-60.
               21.  Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, et al. Advanced hepatocellular carcinoma: early evaluation of response to
                   bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results. Radiology 2011;258:291-300.
               22.  Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic
                   review. Eur J Cancer 2007;43:979-92.
               23.  Chen J, Chen C, Xia C, Huang Z, Zuo P, et al. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma
                   using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density. Abdom Radiol (NY)
                   2018;43:1393-403.
               24.  Jiang K, Al-Diffhala S, Centeno BA. Primary liver cancers-part 1: histopathology, differential diagnoses, and risk stratification. Cancer
                   Control 2018;25:1073274817744625.
               25.  Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging 2011;36:232-43.
               26.  International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic
                   diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology
                   2009;49:658-64.
               27.  Calistri L, Castellani A, Matteuzzi B, Mazzoni E, Pradella S, et al. Focal liver lesions classification and characterization: what value do
                   DWI and ADC have? J Comput Assist Tomogr 2016;40:701-8.
               28.  Di Pietropaolo M, Briani C, Federici GF, Marignani M, Begini P, et al. Comparison of diffusion-weighted imaging and gadoxetic acid-
                   enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules. Clin Imaging 2015;39:468-
                   75.
               29.  Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, et al. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma:
                   imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J
                   Roentgenol 2009;193:438-44.
               30.  Heo SH, Jeong YY, Shin SS, Kim JW, Lim HS, et al. Apparent diffusion coefficient value of diffusion-weighted imaging for
                   hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor. Korean
                   J Radiol 2010;11:295-303.
               31.  Nakanishi M, Chuma M, Hige S, Omatsu T, Yokoo H, et al. Relationship between diffusion-weighted magnetic resonance imaging and
                   histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 2012;19:1302-9.
               32.  Li YT, Cercueil JP, Yuan J, Chen W, Loffroy R, et al. Liver intravoxel incoherent motion (IVIM) magnetic resonance imaging: a
                   comprehensive review of published data on normal values and applications for fibrosis and tumor evaluation. Quant Imaging Med Surg
                   2017;7:59-78.
               33.  Granata V, Fusco R, Catalano O, Guarino B, Granata F, et al. Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI)
                   for Hepatocellular carcinoma: correlation with histologic grade. Oncotarget 2016;7:79357-64.
               34.  Woo S, Lee JM, Yoon JH, Joo I, Han JK, et al. Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma:
                   correlation with enhancement degree and histologic grade. Radiology 2014;270:758-67.
               35.  Sokmen BK, Sabet S, Oz A, Server S, Namal E, et al. Value of intravoxel incoherent motion for hepatocellular carcinoma grading.
                   Transplant Proc 2019;51:1861-6.
               36.  Wu EX, Cheung MM. MR diffusion kurtosis imaging for neural tissue characterization. NMR Biomed 2010;23:836-48.
               37.  Cao L, Chen J, Duan T, Wang M, Jiang H, et al. Diffusion kurtosis imaging (DKI) of hepatocellular carcinoma: correlation with
                   microvascular invasion and histologic grade. Quant Imaging Med Surg 2019;9:590-602.
               38.  Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 2010;23:698-710.
               39.  Hennedige TP, Hallinan JT, Leung FP, Teo LL, Iyer S, et al. Comparison of magnetic resonance elastography and diffusion-weighted
                   imaging for differentiating benign and malignant liver lesions. Eur Radiol 2016;26:398-406.
               40.  Thompson SM, Wang J, Chandan VS, Glaser KJ, Roberts LR, et al. MR elastography of hepatocellular carcinoma: correlation of tumor
                   stiffness with histopathology features-Preliminary findings. Magn Reson Imaging 2017;37:41-5.
   20   21   22   23   24   25   26   27   28   29   30